All In Biotech

Drug Trial Radar · NCT07675785

PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali

Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, & Protective Efficacy of Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) in Healthy African Adult Women of Childbearing Potential in Mali

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Jul 15, 2028

Study completion Apr 2030

Sponsor

Lead sponsor
Sanaria Inc.Industry
Sponsor type
Industry
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); University of the Sciences, Techniques and Technologies of Bamako; Malaria Research and Training Center, Bamako, Mali
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 38 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10\^5 PfSPZ or placebo in healthy WOCBP, who are on pregnancy prevention during vaccination, but report plans to become pregnant in the near future. Participants will be randomized into two arms. Arm 1: (n= 150) will receive 3 doses of PfSPZ-LARC2 Vaccine (2x10\^5 PfSPZ) via direct venous inoculation (DVI) at 1, 6, 29 days. Arm 2: (n= 150) will receive 3 doses of normal saline (placebo) injection via DVI at 1, 6, 29 days. All volunteers will receive antimalarial treatment with artemether/lumefantrine (AL) \~2 to 4 weeks prior to 1st (study day -14 to -28) and \~2 weeks prior to 3rd injection (study day 44). Participants will be monitored for safety, tolerability, immunogenicity, and malaria infection during the follow-up period. Participants will also be monitored closely for pregnancy as well post 3rd injection through the entire planned study duration (2 years post dose 1). If pregnant, women will be followed during the course of their pregnancy and for at least 1 year post-delivery (as well as their offspring) for safety and malaria infection. Malaria infections in participants and their offspring will be classified as asymptomatic or symptomatic (clinical cases).

Conditions

  • Malaria (Plasmodium Falciparum)

Interventions

  • PfSPZ-LARC2 VaccineBiological

    PfSPZ-LARC2 Vaccine (2x105 PfSPZ) via direct venous inoculation (DVI)

  • Normal SalineOther

    Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of local AEsTime frame: Day 1 to Day 35
  2. Incidence of systemic adverse eventsTime frame: Day 1 to Day 35
  3. P.falciparum blood stage infection defined as time to first positive P.falciparum blood smear following 3rd injection to over 24 weeksTime frame: Day 29 to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Sciences, Techniques and Technology, Bamako (USTTB)

    Bamako, Mali · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.